Search Videos by Topic or Participant
Browse by Series:

Cost Effectiveness of Gene Expression Testing

Insights From:F. Anthony Greco, MD, Sarah Cannon Cancer Center; Suresh S. Ramalingam, MD, Emory University
Published: Tuesday, Sep 22, 2015

 
Novel drug therapies are effective, but expensive, states Suresh S. Ramalingam, MD. Using appropriate gene expression technology can help control costs by helping determine which treatments are most likely to work for that individual. Testing the appropriate patient population is important, so that potential mutations or targets are not missed, says Ramalingam. Individualizing care with targeted drugs may prolong survival, improve quality of life, and result in fewer hospitalizations and adverse events, adds Ramalingam.

The bioT3 platform, which includes CancerTREATMENT ID and CancerTYPE ID, helps determine cancer type in patients with an unknown or unclear diagnosis and was designed to try and control cost, notes F. Anthony Greco, MD. The tests are currently available at no-cost to Medicare beneficiaries, adds Greco. While molecular tests are becoming less expensive, testing for a growing number of mutations confers higher costs and increases the time required to obtain results, says Greco.
 
Slider Left
Slider Right

 
Novel drug therapies are effective, but expensive, states Suresh S. Ramalingam, MD. Using appropriate gene expression technology can help control costs by helping determine which treatments are most likely to work for that individual. Testing the appropriate patient population is important, so that potential mutations or targets are not missed, says Ramalingam. Individualizing care with targeted drugs may prolong survival, improve quality of life, and result in fewer hospitalizations and adverse events, adds Ramalingam.

The bioT3 platform, which includes CancerTREATMENT ID and CancerTYPE ID, helps determine cancer type in patients with an unknown or unclear diagnosis and was designed to try and control cost, notes F. Anthony Greco, MD. The tests are currently available at no-cost to Medicare beneficiaries, adds Greco. While molecular tests are becoming less expensive, testing for a growing number of mutations confers higher costs and increases the time required to obtain results, says Greco.
 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x